Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.
about
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) studySuicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxineRisk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug AdministrationSuicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical CorrelatesMeta-analysis of risk factors for nonsuicidal self-injuryThe relation between child maltreatment and adolescent suicidal behavior: a systematic review and critical examination of the literatureSuicidality associated with antiepileptic drugs: implications for the treatment of neuropathic pain and fibromyalgiaNon-psychotropic medication and risk of suicide or attempted suicide: a systematic reviewNear infrared spectroscopy study of the frontopolar hemodynamic response and depressive mood in children with major depressive disorder: a pilot studyEvaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trialMeta-analysis of clinical trial safety data in a drug development program: answers to frequently asked questions.Identifying suicidal behavior among adolescents using administrative claims data.Magnetic resonance imaging markers of suicide attempt and suicide risk in adolescents.Emergency department and inpatient coding for self-harm and suicide attempts: Validation using clinician assessment data.Secondary prevention of suicideA pragmatic, randomized, controlled study evaluating the impact of access to smoking cessation pharmacotherapy coverage on the proportion of successful quitters in a Canadian population of smokers motivated to quit (ACCESSATION).A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorderThe Problematic Label of Suicide Gesture: Alternatives for Clinical Research and Practice.Gender differences in suicide attempters: a retrospective study of precipitating factors for suicide attempts at a critical emergency unit in Japan.Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable?The statistics of suicide.Interactive Voice Response and Text-based Self-report Versions of the Electronic Columbia-Suicide Severity Rating Scale Are Equivalent.Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.Evidence for the management of adolescent depression.Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinicsSuicidal behavior disorder as a diagnostic entity in the DSM-5 classification system: advantages outweigh limitations.Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study.The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial.Effect of exposure to suicidal behavior on suicide attempt in a high-risk sample of offspring of depressed parents.Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.Pharmacogenomics of suicidal events.Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trialEvaluating the predictive validity of suicidal intent and medical lethality in youth.Using structured telephone follow-up assessments to improve suicide-related adverse event detectionA pilot study to assess smokeless tobacco use reduction with varenicline.The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder.
P2860
Q24607463-620E8EE8-213B-4DA0-AA3C-BD337C7FDE39Q24612175-9E3C71C3-F3E9-48BD-9FB7-A975927B9C18Q24653558-06B6FE9A-AA57-4136-9CB6-BD793558915AQ26738486-61E6D03C-763C-446B-9013-D94D38AA5A51Q26785384-CD80D21B-B882-46B9-A612-7CE055609112Q26827545-91E667BB-EE26-4CF1-8AAE-9CEAE30EA753Q27009981-7DC1AF22-B7AB-49C4-A62C-51074FF684F8Q28078315-C1B9B5C5-DD32-4681-A9F9-AD3E55B623D6Q28539086-62ECE5B9-28E1-43F7-8DDB-AC9026D4D45BQ30434663-87C7EA01-14E3-4D72-A66F-0CB4791C8D32Q30578166-9AE40764-1617-46B4-BC97-E11C56B33F48Q30588879-20757977-5320-4E0C-AD31-D5945FDE0023Q30938803-9B309B84-7CA8-4F53-B19D-299D2F901F6CQ31165566-83F36E5F-2812-4061-8812-EE49EEC73CADQ33598683-6A20297B-9C8B-4FCF-8581-5AF2B3118B53Q33618099-56B931C2-B162-4456-A5FC-B398A29BC38EQ33632093-0AE357D0-BA0E-4039-8653-A6F373685F40Q33632732-F6F02DCD-AFC1-4538-8921-A5CE4D2FE706Q33635412-65057B09-8260-4AC3-B1C2-E374C3EAC418Q33646372-598B912C-BD89-4C10-8083-14FF34063BD3Q33659631-3DC777D4-2E65-4D98-8408-E1988B40E8D8Q33669513-5B86F04A-D366-4658-A99F-3803C6D7F6ACQ33744415-2953B5F5-1C7C-4831-B8EB-02B1185FB779Q33745841-3D807425-C14B-42F5-927B-9B2BF41276B0Q33767175-E551FBE9-91D6-4A02-BAE9-458FFA4D89D4Q33819692-2D8E94DD-E7FE-49F7-B37D-F3AF2987105BQ33854297-0AD11063-12F2-4251-A0A6-1A9CB0F33826Q33915477-21A9645F-B2C9-4097-8567-A23DFF419B3CQ33919579-EE269C19-0BA9-4151-AB9A-DB39B1D5EF1BQ33940277-F6661811-A665-427E-8F2D-D43BFE125D26Q34042140-1C0BD232-85F7-406E-B91C-F2FF7874A354Q34063590-741138B6-CD31-41CE-99C1-21A15FD48F8FQ34066818-17311F32-7E69-43C2-857C-D51162E81079Q34113960-22D81157-3664-4898-BB4F-F234E29FD92FQ34116684-D94E50BA-F75A-4B5B-B250-0B5FA01BDBA6Q34129246-5837CA9D-7F0F-4C7B-9F19-2C3FE678040CQ34129556-0AEB36D7-4997-4059-834F-CF3018D4FA83Q34166333-5E9293F4-1DFD-48A1-A7F9-41A10C88FE67Q34242471-3FA21FAA-6B16-4630-A8FA-7531F73B238DQ34260074-0B4F2817-ABEE-4C5D-9B30-39CC2E6575F3
P2860
Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Columbia Classification Algori ...... k analysis of antidepressants.
@en
Columbia Classification Algorithm of Suicide Assessment
@nl
type
label
Columbia Classification Algori ...... k analysis of antidepressants.
@en
Columbia Classification Algorithm of Suicide Assessment
@nl
prefLabel
Columbia Classification Algori ...... k analysis of antidepressants.
@en
Columbia Classification Algorithm of Suicide Assessment
@nl
P2093
P2860
P921
P1476
Columbia Classification Algori ...... k analysis of antidepressants.
@en
P2093
Kelly Posner
Madelyn Gould
Mark Davies
P2860
P304
P356
10.1176/AJP.2007.164.7.1035
P407
P577
2007-07-01T00:00:00Z